ESC Congress 2026 to Feature 59 Late-Breaking Clinical Trials

Source: ESC Congress 2026. July 2026

* 59 late-breaking trials will be presented in 12 Hot Line sessions at ESC Congress 2026 (Munich, Aug. 28–31).
* The program includes major studies on ACS, heart failure, atrial fibrillation, TAVI, hypertrophic cardiomyopathy, cardiac amyloidosis, imaging, digital health, and prevention.
* Key highlighted trials include LIBREXIA ACS, PRESC1SE-MI, CARDIO-TTRansform, ACACIA-HCM, and STAREE.
* ESC expects several of these studies to shape future clinical guidelines and cardiovascular practice.

https://www.escardio.org/news/press/press-releases/hot-lines-revealed–the-trials-that-will-make-the-headlines-at-esc-congress-2026/?

888 Views